Search Videos by Topic or Participant
Browse by Series:

Role of Genetic Testing in Breast Cancer

Discussant: Francisco J. Esteva, MD, PhD, NYU
Published: Friday, Mar 20, 2015
For High-Definition, Click
The paradigm in breast cancer has changed from a purely histopathological diagnosis to a more genomic-based or molecular-based focus, Francisco J. Esteva, MD, PhD, states. Treatments are now based on information beyond just the architecture of the cancer to examine which proteins are expressed (eg, estrogen receptor, progesterone receptor, HER2, etc.).

Several multigene panel tests can be used to delve deeper into the genomic profiling of a patient’s cancer, including Oncotype DX, Mammaprint, and Prosigna, Esteva explains. These tests can be used to categorize patients into low-, intermediate- and high-risk groups, which in turn can determine a patient’s potential benefit from chemotherapy versus targeted therapy.
Slider Left
Slider Right
For High-Definition, Click
The paradigm in breast cancer has changed from a purely histopathological diagnosis to a more genomic-based or molecular-based focus, Francisco J. Esteva, MD, PhD, states. Treatments are now based on information beyond just the architecture of the cancer to examine which proteins are expressed (eg, estrogen receptor, progesterone receptor, HER2, etc.).

Several multigene panel tests can be used to delve deeper into the genomic profiling of a patient’s cancer, including Oncotype DX, Mammaprint, and Prosigna, Esteva explains. These tests can be used to categorize patients into low-, intermediate- and high-risk groups, which in turn can determine a patient’s potential benefit from chemotherapy versus targeted therapy.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: How Do We Leverage PARP Inhibition Strategies in the Contemporary Treatment of Breast Cancer?May 31, 20191.5
Community Practice Connections™: A Better Way to Stop Pain: Paths Toward Responsible Postsurgical Pain Management for Patients With Breast CancerMay 31, 20191.5
Publication Bottom Border
Border Publication
x